Literature DB >> 33618709

Transient accumulation of subretinal fluid after half-fluence photodynamic therapy in neovascular age-related macular degeneration.

Min Ho Kim1, Yoo-Ri Chung2, Ji Hun Song3.   

Abstract

BACKGROUND: Photodynamic therapy (PDT) is known to occlude choroidal neovascularisation selectively, and there have been several reports on its adverse effects on the normal choroid and retinal pigment epithelium, resulting in decreased vision.
METHODS: This retrospective interventional case series aimed to investigate the changes in visual acuity and retinal thickness in the immediate post-treatment period after half-fluence PDT, administered alone or with anti-vascular endothelial growth factor and steroids, in 29 eyes (26 patients) with neovascular age-related macular degeneration. The patients' best-corrected visual acuity (BCVA) and central foveal thickness (CFT) on optical coherence tomography images were measured 1 day, 1 week, and 1 month post-treatment.
RESULTS: Compared to the pre-treatment CFT (270.38 μm), the mean CFT was significantly increased 1 day post-treatment (387.07 μm, P = 0.001), which then started to decrease, with a mean CFT of 269.32 μm (P = 0.516) at 1 week, and of 240.66 μm (P = 0.066) at 1 month post-treatment. All CFT increases were due to the accumulation of subretinal fluid (SRF), rather than the intraretinal or subretinal pigment epithelium fluid. Relative to the pre-treatment BCVA (0.59 logMAR), the mean BCVA at 1 day (0.74 logMAR, P = 0.005) and 1 week (0.75 logMAR, P = 0.002) post-treatment was significantly deteriorated; however, it recovered to 0.62 logMAR at 1 month. The patterns of change in CFT and BCVA did not differ according to treatment modality.
CONCLUSIONS: Half-fluence PDT resulted in accumulation of SRF in the immediate post-treatment period; this damage mostly recovered within a week, and the BCVA was restored within a month.

Entities:  

Keywords:  Blood-retinal barrier; Photodynamic therapy; Retinal pigment epithelium

Mesh:

Substances:

Year:  2021        PMID: 33618709      PMCID: PMC7901101          DOI: 10.1186/s12886-021-01867-w

Source DB:  PubMed          Journal:  BMC Ophthalmol        ISSN: 1471-2415            Impact factor:   2.209


  31 in total

1.  Comparison of photodynamic therapy, ranibizumab/bevacizumab or combination in the treatment of myopic choroidal neovascularisation: a 9-year-study from a single centre.

Authors:  Pukhraj Rishi; Ekta Rishi; Muna Bhende; Vishvesh Agarwal; Chinmayi H Vyas; Meenakshi Valiveti; Pramod Bhende; Chetan Rao; Pradeep Susvar; Parveen Sen; Rajiv Raman; Vikas Khetan; Vinata Murali; Dhanashree Ratra; Tarun Sharma
Journal:  Br J Ophthalmol       Date:  2016-01-20       Impact factor: 4.638

2.  Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Ichiro Maruko; Tomohiro Iida; Yukinori Sugano; Masaaki Saito; Tetsuju Sekiryu
Journal:  Am J Ophthalmol       Date:  2011-02-04       Impact factor: 5.258

3.  Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors: 
Journal:  Arch Ophthalmol       Date:  1999-10

4.  Photodynamic effects on choroidal neovascularization and physiological choroid.

Authors:  Ursula Schmidt-Erfurth; Stephan Michels; Irene Barbazetto; Horst Laqua
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-03       Impact factor: 4.799

5.  Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.

Authors:  Eva Smretschnig; Siamak Ansari-Shahrezaei; Stefan Hagen; Carl Glittenberg; Ilse Krebs; Susanne Binder
Journal:  Retina       Date:  2013-02       Impact factor: 4.256

6.  Vascular targeting in photodynamic occlusion of subretinal vessels.

Authors:  U Schmidt-Erfurth; T Hasan; E Gragoudas; N Michaud; T J Flotte; R Birngruber
Journal:  Ophthalmology       Date:  1994-12       Impact factor: 12.079

Review 7.  Photodynamic therapy for polypoidal choroidal vasculopathy.

Authors:  Patrycja Nowak-Sliwinska; Hubert van den Bergh; Michel Sickenberg; Adrian H C Koh
Journal:  Prog Retin Eye Res       Date:  2013-10-15       Impact factor: 21.198

8.  Influence of verteporfin photodynamic therapy on inflammation in human choroidal neovascular membranes secondary to age-related macular degeneration.

Authors:  Olcay Tatar; Annemarie Adam; Kei Shinoda; Efdal Yoeruek; Peter Szurman; Silvia Bopp; Claus Eckardt; Karl Ulrich Bartz-Schmidt; Salvatore Grisanti
Journal:  Retina       Date:  2007 Jul-Aug       Impact factor: 4.256

9.  Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD).

Authors:  V H Fingar; P K Kik; P S Haydon; P B Cerrito; M Tseng; E Abang; T J Wieman
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

10.  Prevalence of Age-Related Macular Degeneration in Europe: The Past and the Future.

Authors:  Johanna M Colijn; Gabriëlle H S Buitendijk; Elena Prokofyeva; Dalila Alves; Maria L Cachulo; Anthony P Khawaja; Audrey Cougnard-Gregoire; Bénédicte M J Merle; Christina Korb; Maja G Erke; Alain Bron; Eleftherios Anastasopoulos; Magda A Meester-Smoor; Tatiana Segato; Stefano Piermarocchi; Paulus T V M de Jong; Johannes R Vingerling; Fotis Topouzis; Catherine Creuzot-Garcher; Geir Bertelsen; Norbert Pfeiffer; Astrid E Fletcher; Paul J Foster; Rufino Silva; Jean-François Korobelnik; Cécile Delcourt; Caroline C W Klaver
Journal:  Ophthalmology       Date:  2017-07-14       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.